Multiple Myeloma Research Foundation Holds First Patient Summit in Denver
The first-ever Multiple Myeloma Research Foundation (MMRF) Patient Summit was held March 25 in Denver to help patients and caregivers learn more about…
Myeloma
New Cancer Drug-delivery Vehicle May Provide More Precise Treatment, Study Shows
Antibody-drug conjugates (ADCs), a class of drugs in which a cancer-targeting therapy is attached to a specific monoclonal antibody without harming healthy cells, continue to…
BioLineRx’s BL-8040 Shows Promise in Bone Marrow Transplants for Blood Cancers
BioLineRx’s investigational drug BL-8040 has demonstrated positive interim results from a Phase 2 trial as a monotherapy for the mobilization and collection of donor blood stem…
Experimental LCL161 Combo Therapy Boosts Immunity and Shrinks Tumors in Myeloma Patients
By activating the immune system, the experimental drug LCL161 has the potential to fight myeloma in both mice and humans, according to a new study by…
Myeloma UK Launches Reolysin Combo Trial for Relapsing Myeloma Patients
The cancer charity Myeloma UK has launched a Phase 1 clinical trial testing Reolysin (pelareorep), a modulator of the immune system and cytotoxic agent, in myeloma…
Patient Power Backs Multiple Myeloma Patient’s Quest to Run 101st Marathon
Don Wright, who recently finished his 100th marathon while on active treatment for multiple myeloma, will continue running, but now with the support of the…
WT-1 Cancer Vaccine Could Benefit Myeloma Patients Undergoing Stem Cell Transplants
Multiple myeloma patients undergoing autologous stem cell transplants (ASCT) may strongly benefit from SELLAS‘ WT-1 cancer vaccine, galinpepimut-S, according to recent data from a…
Early Studies of 2 Possible Multiple Myeloma Treatments to Be Presented at AACR
GlycoMimetics will present preclinical research at the American Association for Cancer Research (AACR) Annual Meeting 2017, demonstrating the potential of two drug candidates,…
Celyad’s Trial Evaluating CAR T-cells in 7 Cancers to Start Enrolling Patients in US
Celyad is ready to enroll patients in its Phase 1 THINK trial in Rosewell Park, N.Y. and the University of Pittsburgh Medical Center in Pennsylvania after gaining…
Kyprolis Significantly Improved Survival of Relapsed Myeloma Patients in Phase 3 Study
Patients with relapsed or refractory multiple myeloma who receive a combination of Kyprolis (carfilzomib) and dexamethasone have significantly better survival rates than those receiving Velcade (bortezomib) plus…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML